Cleared Special

K201713 - AVVIGO Guidance System

K201713 is the FDA 510(k) clearance for AVVIGO Guidance System by Boston Scientific Corporation. It is a Class 2 Cardiovascular device (product code DQK) cleared through the Special 510(k) pathway after a 30-day FDA review.

K201713 · Boston Scientific Corporation · Cardiovascular device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jul 2020
Decision
30d
Days
Class 2
Risk

K201713 is an FDA 510(k) clearance for the AVVIGO Guidance System. Classified as Computer, Diagnostic, Programmable (product code DQK), Class II - Special Controls.

Submitted by Boston Scientific Corporation (Maple Grove, US). The FDA issued a Cleared decision on July 23, 2020 after a review of 30 days - a notably fast clearance cycle.

This device falls under the Cardiovascular FDA review panel, regulated under 21 CFR 870.1425 - the FDA cardiovascular device oversight framework. As a Special 510(k), this submission covers a manufacturer modification to an existing cleared device rather than a new device introduction.

Device pattern: Iterative device modification. Low regulatory complexity profile. This Special 510(k) clearance confirms that the manufacturer's modifications remained within the established regulatory envelope of the original cleared device.

View all Boston Scientific Corporation devices

Submission Details

510(k) Number K201713 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received June 23, 2020
Decision Date July 23, 2020
Days to Decision 30 days
Submission Type Special
Review Panel Cardiovascular (CV)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
95d faster than avg
Panel avg: 125d · This submission: 30d
Pathway characteristics
Modification to existing cleared device.

Device Classification

Product Code DQK Computer, Diagnostic, Programmable
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 870.1425
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Cardiovascular devices follow this clearance model.

Regulatory Peers - DQK Computer, Diagnostic, Programmable

All 251
Devices cleared under the same product code (DQK) and FDA review panel - the closest regulatory comparables to K201713.
HemoSphere Advanced Monitoring Platform, HemoSphere ClearSight Module
K201446 · Edwards Lifesiences, LLC · Oct 2020
VX1
K201298 · Volta Medical · Sep 2020
VIVO
K200313 · Catheter Precision, Inc. · Sep 2020
EnSite Precision Cardiac Mapping System v2.6, EnSite Precision Software Installation v2.6, EnSite LiveView Dynamic Display Software License
K201148 · Abbott Medical · Jun 2020
EnSite Velocity Cardiac Mapping System, EnSite Precision Cardiac Mapping System
K201181 · Abbott Medical · Jun 2020
iLab Polaris Multi-Modality Guidance System
K201178 · Boston Scientific · May 2020